Vitamin C
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BEROCCA PN | — | 1947-07-28 | fda.gov ↗ |
Trials 297 · started per year
Also used as a comparator or background therapy in 97 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07121127 Background | Jul 2026 → Aug 2029 expected | age-related macular degeneration | Zhiming Yan | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT01210430 Comparator | Jul 2010 → Jun 2015 | postural orthostatic tachycardia syndrome | New York Medical College | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03166787 Background | Aug 2017 → Apr 2020 | — | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00325572 Comparator | Nov 2006 → Dec 2010 | autism spectrum disorder | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07070024 Comparator | Jul 2025 → Jul 2026 overdue | gingival disorder | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04715022 Comparator | Jun 2021 → Aug 2026 overdue | hypertensive disorder | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04708340 Comparator | Mar 2021 → Oct 2022 | COVID-19, acute respiratory distress syndrome | Reven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04591600 Background | Jul → Sep 2020 | COVID-19 | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| Phase 1/2 | NCT04357782 Comparator | Apr → Oct 2020 | COVID-19 | Hunter Holmes Mcguire Veteran Affairs Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03522922 Comparator | Jun 2016 → Feb 2018 | acne | Sohag University | Completed | No outcome recorded |
| Phase 1/2 | NCT02206425 Background | Sep 2014 → Jan 2018 | plasma cell myeloma | Oncotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01434121 Comparator | May 2010 → Sep 2012 | acute hypotension, acute lung injury, infectious disease with sepsis | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT00469209 Comparator | Jun 2006 → Dec 2008 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT05913180 Comparator | Sep 2023 → Aug 2026 overdue | urinary tract infection | American University of Beirut Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04921189 Comparator | Dec 2021 → Dec 2024 | cardiac arrest, post-cardiac arrest syndrome | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04291508 Comparator | Oct 2021 → Apr 2023 | acute respiratory distress syndrome, infectious disease with sepsis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04687176 Background | Jan 2021 → Dec 2025 overdue | acute promyelocytic leukemia | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT04689815 Background | Jan 2021 → Dec 2023 | acute myeloid leukemia with mutated NPM1 | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT04344184 Comparator | Dec 2020 → Jun 2022 | COVID-19, acute lung injury | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT05398965 Background | Nov 2020 → Jan 2021 | COVID-19 | Hasanuddin University | Completed | No outcome recorded |
| Phase 2 | NCT04279197 Background | Apr 2020 → Mar 2021 | postinflammatory pulmonary fibrosis | ShuGuang Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04071977 Comparator | Mar 2020 → Oct 2021 | diabetes mellitus, diabetic retinopathy | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT03509662 Comparator | Oct 2019 → Feb 2024 | cardiac arrest | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 2 | NCT03968042 Background | Jun 2019 → Dec 2021 | brain injury | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03829683 Comparator | Apr 2019 → Mar 2022 | alcoholic hepatitis, infectious disease with sepsis | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT03624270 Background | Aug 2018 → Sep 2023 | acute promyelocytic leukemia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT03333278 Comparator | May 2018 → Jul 2019 | infectious disease with sepsis | Australian and New Zealand Intensive Care Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT03148236 Comparator | Sep 2017 → Mar 2018 | atrial fibrillation | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT03269799 Comparator | Aug 2017 → Feb 2018 | periodontitis, type 2 diabetes mellitus | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT03223519 Comparator | Jul → Nov 2017 | — | Spherium Biomed | Completed | No outcome recorded |
| Phase 2 | NCT03106948 Comparator | Feb 2017 → Jan 2018 | vascular occlusion disorder | Southeast Renal Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02734147 Comparator | Apr 2016 → Oct 2017 | infectious disease with sepsis | Christiana Care Health Services | Terminated | No outcome recorded |
| Phase 2 | NCT02106975 Comparator | Apr 2014 → Nov 2017 | acute lung injury, infectious disease with sepsis | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT02058212 Comparator | Mar → Oct 2013 | endometriosis | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT01587963 Comparator | Feb 2013 → Feb 2014 | — | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2 | NCT03524846 Comparator | Apr → Oct 2011 | — | National Taiwan University Hospital Hsin-Chu Branch | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07476443 Comparator | Apr 2026 → May 2027 expected | cisplatin toxicity | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05310760 Comparator | Mar → Jul 2022 | rickets | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT03338569 Comparator | Dec 2017 → Jun 2020 | infectious disease with sepsis | University of Minnesota | Completed | No outcome recorded |
| Phase 2/3 | NCT02083575 Comparator | Apr 2014 | beta-thalassemia major | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00064753 Background | May 2002 → Oct 2011 | cardiovascular disorder, chronic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT06044194 Comparator | Mar 2023 → Sep 2024 | heart failure | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
| Phase 3 | NCT04955145 Comparator | Jun 2021 → Jan 2022 | end stage renal failure | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT04747795 Comparator | Jun 2021 → Aug 2023 | infectious disease with sepsis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 3 | NCT04810728 Background | Jun → Dec 2020 | COVID-19 | Baiturrahmah University | Completed | No outcome recorded |
| Phase 3 | NCT04409483 Background | Jun → Dec 2020 | COVID-19 | Epicentre | Withdrawn | No outcome recorded |
| Phase 3 | NCT04197115 Comparator | Sep 2019 → Aug 2020 | infectious disease with sepsis | IMSS Hospital General de Zona 11, Piedras Negras | Completed | No outcome recorded |
| Phase 3 | NCT01283646 Comparator | Oct 2011 → May 2012 | — | EMS | Completed | No outcome recorded |
| Phase 3 | NCT01295450 Comparator | Apr → Aug 2011 | eating disorder | MDCPharma Produtos Farmaceuticos LTDA | Unknown | No outcome recorded |
| Phase 3 | NCT01266928 Comparator | Jan → Nov 2011 | preterm premature rupture of the membranes | Erzincan Military Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01107730 Comparator | Apr 2010 → Apr 2015 | atrial fibrillation | Attikon Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00953212 Comparator | Aug 2009 → Jan 2012 | atrial fibrillation, atrial flutter | MaineHealth | Completed | No outcome recorded |
| Phase 3 | NCT00631111 Comparator | Nov 2007 → Apr 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT06224881 Comparator | Dec 2021 → Jan 2023 | infectious disease with sepsis | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT06556134 Comparator | Jul 2021 → Jul 2023 | anemia due to chronic disorder | Centre Hospitalier Hassan II - Fès | Completed | No outcome recorded |
| Phase 4 | NCT03830489 Comparator | Feb → Oct 2019 | — | Hospital Universitario de Canarias | Completed | No outcome recorded |
| Phase 4 | NCT03698474 Comparator | Oct 2018 → Feb 2019 | — | Tomas Bata Hospital, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT03581149 Comparator | Mar 2018 → Jul 2020 | ulcerative colitis | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03188445 Comparator | Jul 2017 → Jun 2020 | iron deficiency anemia | Pharmacosmos A/S | Completed | No outcome recorded |
| Phase 4 | NCT02956057 Comparator | Nov 2016 → May 2017 | — | Tomas Bata Hospital, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT02761213 Comparator | Apr 2016 → Aug 2017 | colonic disorder | Bo-In Lee | Completed | No outcome recorded |
| Phase 4 | NCT02639741 Comparator | Nov 2014 → Jan 2020 | — | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT02209636 Background | Sep 2014 → Jun 2019 | cardiovascular disorder, chronic kidney disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT02355197 Comparator | Jan 2013 → Feb 2015 | gestational diabetes | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT01558622 Comparator | Mar → May 2012 | — | Kavaklıdere Umut Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02780505 Comparator | Nov 2011 → Apr 2012 | anemia | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01332578 Background | May → Jun 2011 | common cold, influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01322061 Comparator | Nov 2010 → Jul 2011 | cholecystitis | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01090895 Comparator | Mar 2010 → Oct 2017 | intermediate coronary syndrome | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02620345 Background | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00869427 Comparator | Mar 2009 → Jun 2011 | spinal cord injury, urinary tract infection | Sunnaas Rehabilitation Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00519337 Comparator | Oct 2008 → Oct 2009 | — | Hartford Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01167569 Comparator | Oct 2007 → Apr 2013 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT00431691 Comparator | Sep 2006 → Dec 2007 | escherichia coli infection, retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01033526 Background | Oct 2005 → Jun 2007 | common cold | Bayer | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT07366502 Comparator | Sep 2025 → Jul 2026 overdue | disorder of iron metabolism and transport, iron deficiency anemia | Medeni Şermet | Recruiting | No outcome recorded |
| — | NCT06936592 Comparator | Apr → Oct 2025 overdue | gingival recession | Minia University | Not yet recruiting | No outcome recorded |
| — | NCT06597682 Background | Mar 2025 → Jul 2027 expected | long COVID-19 | Huashan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06749756 Comparator | Feb 2025 → Feb 2026 overdue | infectious disease with sepsis | Fan Zeng | Recruiting | No outcome recorded |
| — | NCT06374771 Comparator | Apr → Jun 2024 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT06009744 Comparator | Aug 2023 → Dec 2028 expected | intestinal fistula | Hospital Juarez de Mexico | Recruiting | No outcome recorded |
| — | NCT05977166 Comparator | Mar → Jun 2022 | long COVID-19 | Cairo University | Completed | No outcome recorded |
| — | NCT05930002 Comparator | Jul 2021 → Sep 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| — | NCT04682574 Comparator | Nov 2020 → Feb 2022 | COVID-19 | University of Lahore | Completed | No outcome recorded |
| — | NCT04216459 Comparator | Feb → Nov 2020 | infectious disease with sepsis | Mansoura University | Completed | No outcome recorded |
| — | NCT04463459 Comparator | Oct 2019 → Jul 2020 | breast cancer | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| — | NCT03391830 Comparator | Jan 2018 → Jan 2020 | acute kidney injury | Mansoura University | Completed | No outcome recorded |
| — | NCT03258684 Comparator | Sep 2017 → Feb 2019 | infectious disease with sepsis | Zhujiang Hospital | Completed | No outcome recorded |
| — | NCT03218280 Comparator | Jan 2017 → Nov 2019 | — | Romanian Society of Anesthesia and Intensive Care | Unknown | No outcome recorded |
| — | NCT03659058 Comparator | Mar 2016 → Aug 2018 | fibrotic liver disease | Zagazig University | Completed | No outcome recorded |
| — | NCT02799134 Comparator | Nov 2015 → Apr 2017 | — | qinshaozheng | Completed | No outcome recorded |
| — | NCT03260829 Comparator | Jan 2014 → Jan 2015 | impacted teeth, multiple | Cairo University | Completed | No outcome recorded |
| — | NCT00914576 Comparator | Apr 2011 → Jul 2013 | — | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00845130 Background | Sep 2009 → Dec 2014 | disorder of defective peroxisome oxidative status, type 2 diabetes mellitus | In-Young Choi, Ph.D. | Completed | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
| — | NCT00889538 Comparator | Apr 2009 → Sep 2012 | autism, disruptive behavior disorder | University of Louisville | Completed | No outcome recorded |
| — | NCT00624871 Comparator | Apr 2004 → Apr 2006 | brain hypoxia - ischemia, perinatal asphyxia | Al-Azhar University | Completed | No outcome recorded |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 409 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vitamin C | “The aim of this trial is to investigate whether the combined use of cortisol, ascorbic acid (vitamin C), and thiamine during the early post-resuscitation period reduces the...” PMID 40215244 ↗ Apr 2025239“Preclinical studies of pharmacologic doses of vitamin C (ascorbic acid, ascorbate) have shown significant anticancer effects in animal models and tissue culture investigations...” NCT00441207 ↗ “with daily multivitamins [vitamin A (300 microg, as retinol palmitate), vitamin E (6 mg tocopherol equivalents), vitamin B-12 (0.9 microg), vitamin C (15 mg), riboflavin (0.5...” PMID 19535425 ↗ Jun 2009 “This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day,...” NCT05398965 ↗ “Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency...” NCT01897792 ↗ “total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium...” NCT00808470 ↗ “This feasibility study serves to determine if it is possible to perform a powered randomized control trial of high-dose intravenous vitamin C (ascorbic acid) as an adjunctive...” NCT04088591 ↗ “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗ “food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours,...” NCT03494387 ↗ “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗ “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗ “Researchers objectives are to perform a randomized-controlled clinical trial investigating the ability of ascorbic acid(vitamin C) administration to decrease organ dysfunction...” NCT02734147 ↗ “Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “The second therapeutic arm investigates a combination antioxidant therapy (selenium 300 µg, zinc 40 mg, lycopene 45 mg and vitamin C 1.5 g), administered for 10 days.” PMID 40754325 ↗ Aug 2025 “(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks” NCT02062034 ↗ “Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).” NCT06723626 ↗ “One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days” NCT06788132 ↗ “capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)” NCT01266928 ↗ “Treatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models.” PMID 23381814 ↗ Feb 2013 “Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.” NCT00135707 ↗ “ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5 gm diluted in 50 ml normal saline IV within 30 min /6 h” NCT04160676 ↗ “1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery” NCT02355197 ↗ “Vitamin C (VC), also known as L-ascorbic acid, has been shown to have antimicrobial and immunomodulatory properties.” PMID 32641343 ↗ Jul 2020 “Intravenous ascorbate (i.e., ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations” NCT01515046 ↗ “This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.” NCT00339768 ↗ “high dose intravenous vitamin C (IVC) therapy plus very low carbohydrate diet (VLCD) for stage IV colon cancer” NCT04035096 ↗ “Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.” NCT03821714 ↗ “The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels” NCT00534924 ↗ “Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days” NCT03223519 ↗ “The extent to which ascorbic acid (Vitamin C) improves the function of the blood vessels will be determined.” NCT04715022 ↗ “1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).” NCT02455180 ↗ “(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)” NCT04810728 ↗ “containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg” NCT00914576 ↗ “Ascorbic acid (Vitamin C) was given parenterally for the treatment group (2 gm every 8hrs) for 4 days.” NCT06224881 ↗ “Ascorbic acid (vitamin C) is a water-soluble vitamin that may help inhibit the growth of cancer cells.” NCT02516670 ↗ “Durvalumab plus ascorbate (also known as vitamin C), followed by surgical resection of the tumor.” NCT06083454 ↗ “1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.” NCT03800667 ↗ “1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.” NCT04261036 ↗ “Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)” NCT05310760 ↗ “The treatment group will also receive vitamin C 500mg daily to assist with iron absorption.” NCT05423249 ↗ “Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg)” NCT00889538 ↗ “hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT” NCT05157360 ↗ “traditional medical treatment in form of (vitamin D, vitamin C and anticoagulation drugs” NCT05977166 ↗ “Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily” NCT04409483 ↗ “Vitamin C, also called ascorbate, is an essential nutrient for the human body.” NCT06598033 ↗ “we investigated vitamin C (ascorbic acid) as a prophylactic antioxidant drug.” PMID 10636366 ↗ Dec 1999 “Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU” NCT03228238 ↗ “iv vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days” NCT04494451 ↗ “Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements” NCT07121127 ↗ “Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D” NCT04935515 ↗ “Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).” NCT01654861 ↗ “Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein)” NCT00860743 ↗ “Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)” NCT04553666 ↗ “Comparing safety and efficacy of IV Vitamin C in CABG patients” NCT02762331 ↗ “infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer” NCT02992028 ↗ “Vitamin C (ascorbic acid) is the body's main antioxidant” NCT04563000 ↗ “Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg” NCT03659058 ↗ “Active substance: Ascorbic acid (Vitamin C, E 300).” NCT04472000 ↗ “Zinc tablet 80 mg/vitamin C 500mg daily for 42 days” NCT04446104 ↗ “Ascorbic acid is commonly known as Vitamin C.” NCT03684213 ↗ “Hydrocortisone, Vitamin C and Thiamine” NCT03380507 ↗ “vitamin E 100 mg, and vitamin C 50 mg)” PMID 18296460 ↗ Feb 2008 “Vitamin C (My Immuno) 1 scoop per day” NCT04693936 ↗ “Intravenous ascorbic acid/vitamin C” NCT06493370 ↗ “Vitamin C 500mg tablet twice daily” NCT05930002 ↗ “180 mg vitamin C \[ascorbic acid\]” NCT01437826 ↗ “vitamin C (L-ascorbic acid 180 mg)” NCT04071977 ↗ “with 200 mg vitamin c for 3 months” NCT07366502 ↗ “Vitamin C (Ascorbic Acid): 60 mg” NCT00064753 ↗ “Drug: Ascorbic acid (Vitamin C)” NCT06823999 ↗ “Drug: Ascorbic acid (vitamin C)” NCT00624871 ↗ “Vitamin C supplementation 500mg” NCT01319734 ↗ “Vitamin C 300 mg/day, TID, PO.” NCT06601283 ↗ “Vitamin C 1000mg twice/ day” NCT04591600 ↗ “Ascorbic acid (Vitamin C)” NCT00484510 ↗ “Ascorbic acid (vitamin C)” NCT01125449 ↗ “Ascorbic acid (Vitamin C)” NCT07715669 ↗ “Ascorbic Acid (Vitamin C)” NCT01080352 ↗ “IV Vitamin C (12g/day)” NCT05842382 ↗ “vitamin C 400 mg” NCT00963131 ↗ “vitamin C 113mg” NCT00431691 ↗ “Vitamin C” NCT07177079 ↗ “Vitamin C” NCT04153487 ↗ “Vitamin C” NCT01555489 ↗ “Vitamin C” NCT04334967 ↗ |
| Known as | Adenosma Glutinosum | “Drug: * Tenofovir * Phyllanthus Urinaria * Adenosma Glutinosum * Eclipta Prostrata * Ascorbic Acid” NCT01198860 ↗ |
| Known as | ASC | “ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05495243 ↗1“ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05654922 ↗ |
| Known as | ASCOR | “(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic...” NCT04832009 ↗ |
| Known as | Ascor L 500 | “Ascor L 500® (Ascorbic Acid Injection, USP)” NCT02534753 ↗ |
| Known as | ascorbate | “Preclinical studies of pharmacologic doses of vitamin C (ascorbic acid, ascorbate) have shown significant anticancer effects in animal models and tissue culture investigations...” NCT00441207 ↗20“There is increasing interest in using high-dose intravenous ascorbate (IVC) in treating this disease partially because of its low toxicity.” PMID 29215048 ↗ Dec 2017 “Intravenous ascorbate (i.e., ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations” NCT01515046 ↗ “Vitamin C, also called ascorbate, is an essential nutrient for the human body.” NCT06601283 ↗ “Vitamin C, also called ascorbate, is an essential nutrient for the human body.” NCT06598033 ↗ “Ascorbate” NCT01555489 ↗ |
| Known as | Ascorbate-Meglumine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433791 ↗ |
| Known as | ascorbic acid | “Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day,...” NCT04689815 ↗192“The present randomized controlled study was conducted in 28 patients and aimed to investigate the potential nephroprotective effect of intravenous ascorbic acid (2 g every 12...” PMID 25801556 ↗ Mar 2015 “Hospitalized adult patients were randomized to receive low volume (2 L polyethylene glycol and ascorbic acid, 2L PEG+ASC) or standard volume bowel preparation (4 L polyethylene...” PMID 41128725 ↗ Oct 2025 “Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg,...” NCT01295450 ↗ “The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours,...” NCT03494387 ↗ “Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution...” NCT02290093 ↗ “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗ “Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and...” NCT04708340 ↗ “Vitamin C (ascorbic acid) is water-soluble, found throughout the body and is especially highly concentrated in the brain, which has antioxidant and neuroprotective properties.” NCT02127060 ↗ “Induction consisted of up to eight 28-d cycles of bortezomib 1.0 mg/m(2) on days 1, 4, 8 and 11, plus oral ascorbic acid 1 g and oral melphalan 0.1 mg/kg on days 1-4” PMID 19226361 ↗ Feb 2009 “To determine whether regulating vitamin C (ascorbic acid: AA) intake to achieve higher or lower plasma concentrations was associated with improved clinical outcome.” PMID 15724034 ↗ Mar 2005 “Vitamin C (ascorbic acid) is a water-soluble vitamin having anti-inflammatory, immunomodulatory, anti-oxidative, antithrombotic and antiviral properties.” NCT04682574 ↗ “Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g” NCT02540031 ↗ “Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery.” NCT05817851 ↗ “capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)” NCT01266928 ↗ “Eligible participants will be randomized to receive 1 gram of parenteral ascorbic acid and 0.9% normal saline (as placebo) 8 hourly for 7 days” NCT05327348 ↗ “1 liter of polyethylene glycol plus ascorbic acid and bisacodyl 10 mg administered as rescue bowel preparation before repeat colonoscopy.” NCT07557173 ↗ “Intravenous ascorbic acid will be given in a dose based on the plasma vitamin C level to reach a level in the range of 300 to 350 mg/dL.” NCT00626444 ↗ “• Vitamin C (Ascorbic Acid): This intervention involves the administration of vitamin C, which is known for its antioxidant properties.” NCT06847880 ↗ “We previously reduced MRI in rats through a combined antioxidant therapy (CAT) of ascorbic acid, N-acetylcysteine, and deferoxamine.” PMID 38973337 ↗ Jul 2024 “Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia” NCT03418038 ↗ “Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days.” NCT04687176 ↗ “The three cohorts of subjects will receive 50, 75 or 100 grams of intravenous ascorbic acid, three times per week for 8 weeks.” NCT00954525 ↗ “Oral pharmacological grade Vitamin C (Ascorbic Acid) administered at escalating doses and frequencies over a 3-week period.” NCT07612345 ↗ “It has been reported that administration of high-dose ascorbic acid (vitamin C) reduces vascular permeability in animals.” NCT03451266 ↗ “Vitamin C, ascorbic acid, is a water-soluble essential micronutrient commonly found in plants, especially fruits.” NCT06780345 ↗ “Vitamin C , also known as ascorbic acid, is a water-soluble vitamin that has significant antioxidant properties” NCT07070024 ↗ “Ascorbic acid, or vitamin C, is a water-soluble antioxidant that functions as a cofactor for multiple enzymes.” NCT04570254 ↗ “ascorbic acid (AA) enhances the activity of arsenic trioxide (As(2)0(3)) against drug-resistant MM in vitro” PMID 12473574 ↗ Dec 2002 “The Effect of High Dose Versus Low Dose Intravenous Vitamin C (Ascorbic Acid)on Burn Injury Resuscitation” NCT00350077 ↗ “Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)” NCT05658029 ↗ “intravenous ascorbic acid (AA) first in healthy volunteers followed by evaluation in oncology subjects” NCT01833351 ↗ “Patients in Arm 1 will randomized to receive usual care + hydrocortisone, thiamine and ascorbic acid.” NCT04134403 ↗ “One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid” NCT06556134 ↗ “Drug: * Tenofovir * Phyllanthus Urinaria * Adenosma Glutinosum * Eclipta Prostrata * Ascorbic Acid” NCT01198860 ↗ “Ascorbic acid has the ability to inhibit peroxidase and may thus inhibit melanin synthesis.” NCT00172302 ↗ “Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg” NCT04955145 ↗ “hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT” NCT05157360 ↗ “RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks” NCT00419146 ↗ “Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11” NCT00258245 ↗ “Vitamin C, also known as ascorbic acid, is a potent reducing agent and antioxidant” NCT06857734 ↗ “Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day” NCT02620345 ↗ “high-dose, intravenous pharmacological ascorbate (ascorbic acid, vitamin C)” PMID 26201606 ↗ 2015 “Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C).” NCT01364805 ↗ “ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05654922 ↗ “ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05495243 ↗ “Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days” NCT04563000 ↗ “High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders” NCT06313502 ↗ “ascorbic acid is vitamin that can cause gingival depigmentation” NCT03252418 ↗ “High-dose ascorbic acid (vitamin C) therapy (66 mg/kg per hour)” PMID 10722036 ↗ Mar 2000 “infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer” NCT02992028 ↗ “Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)” NCT02761213 ↗ “Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU” NCT03228238 ↗ “Active substance: Ascorbic acid (Vitamin C, E 300).” NCT04472000 ↗ “The other name of the drug: Ascorbic acid.” NCT04404387 ↗ “Ascorbic acid in different ways and doses” NCT02606773 ↗ “in combination with Ascorbic Acid 240 mg” NCT01033526 ↗ “Vitamin C (Ascorbic Acid): 60 mg” NCT00064753 ↗ “Drug: Vitamin C (Ascorbic Acid)” NCT07197749 ↗ “Vitamin C (Ascorbic Acid)” NCT00469209 ↗ “Vitamin C (Ascorbic Acid)” NCT07369232 ↗ “Vitamin C (Ascorbic Acid)” NCT06897384 ↗ “Ascorbic Acid 1000 MG” NCT05913180 ↗ “Ascorbic Acid 1000 MG” NCT03800667 ↗ “Drug: Ascorbic Acid” NCT04035096 ↗ “Drug: Ascorbic Acid” NCT03123107 ↗ “Drug: Ascorbic Acid” NCT02106975 ↗ “Ascorbic acid” NCT03494387 ↗ “Ascorbic Acid” NCT02534753 ↗ “Ascorbic acid” NCT04921189 ↗ “Ascorbic Acid” NCT02516670 ↗ “Ascorbic Acid” NCT02896907 ↗ |
| Known as | ascorbic complex | “The 130 subjects will be randomized into 3 groups: Experimental group 1 will receive a supplement of vitamin C (ascorbic complex) of the Bonusan brand, a daily dose of 1000mg...” NCT04445727 ↗ |
| Known as | ascorbinezuur | “Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).” NCT03509662 ↗ |
| Known as | Bonusan | “The 130 subjects will be randomized into 3 groups: Experimental group 1 will receive a supplement of vitamin C (ascorbic complex) of the Bonusan brand, a daily dose of 1000mg...” NCT04445727 ↗ |
| Known as | CA201A | “This is a multicenter, randomized, double-masked, vehicle-controlled, parallel-arm, Phase 2 study designed to evaluate the safety and efficacy of CA201A, a 5% ascorbic acid...” NCT07694375 ↗ |
| Known as | Cebionâ 1000 per 2/die | “daily 2 g ascorbic acid (Cebionâ 1000 per 2/die) supplementation” NCT00387114 ↗ |
| Known as | E 300 | “Active substance: Ascorbic acid (Vitamin C, E 300).” NCT04472000 ↗ |
| Known as | HDAA | “High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders” NCT06313502 ↗ |
| Known as | High Dose Ascorbic Acid | “High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders” NCT06313502 ↗ |
| Known as | High-dose ascorbate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07177079 ↗ |
| Known as | IVC | “There is increasing interest in using high-dose intravenous ascorbate (IVC) in treating this disease partially because of its low toxicity.” PMID 29215048 ↗ Dec 20172“high dose intravenous vitamin C (IVC) therapy plus very low carbohydrate diet (VLCD) for stage IV colon cancer” NCT04035096 ↗ “Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C).” NCT01364805 ↗ |
| Known as | L-ascorbic acid | “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗8“The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum.” NCT03522922 ↗ “Topical application of L-Ascorbic Acid gel (1000 mg in 5 ml distilled water with CMC and PEG), applied once daily on gingival hyperpigmented areas for 1 month.” NCT07513727 ↗ “Vitamin C (VC), also known as L-ascorbic acid, has been shown to have antimicrobial and immunomodulatory properties.” PMID 32641343 ↗ Jul 2020 “vitamin C (L-ascorbic acid 180 mg)” NCT04071977 ↗ |
| Known as | LAA | “L-ascorbic acid (LAA) modifies the in vitro growth of leukemic cells from approximately 50% of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).” PMID 19284416 ↗ Mar 2009 |
| Known as | Laroscorbine | “Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)” NCT05817851 ↗ |
| Known as | Moviprep | “Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy” NCT03698474 ↗ |
| Known as | My Immuno | “Vitamin C (My Immuno) 1 scoop per day” NCT04693936 ↗ |
| Known as | Neem Mouthrinse | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898091 ↗ |
| Known as | P-AscH- | “Pharmacologic ascorbate (P-AscH-, i.e., intravenous infusions of ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations capable of selective...” PMID 30254147 ↗ Sep 20181“PURPOSE: Pharmacologic ascorbate (P-AscH-) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM).” PMID 37773633 ↗ Jan 2024 |
| Known as | PAA | “Intravenous pharmacologic ascorbic acid (PAA) is one such treatment.” PMID 29438178 ↗ Apr 2018 |
| Known as | pharmacological ascorbate | “Treatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models.” PMID 23381814 ↗ Feb 2013 |
| Known as | polyethylene glycol + ascorbic acid | “Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.” NCT03581149 ↗ |
| Known as | VitC | “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗6“Group 1 received vitamin C (Vit C), Group 2 vitamin E (Vit E), Group 3 n-acetylcysteine (NAC), Group 4 melatonin (MT) and group 5 no treatment.” PMID 37174730 ↗ May 2023 “The aim of this study is to assess the ability of high-dose intravenous vitamin C (Vit-C) to improve post-CA shock.” PMID 39317492 ↗ Sep 2024 “Vitamin C (VitC) is known to directly impair cancer cell growth in preclinical models” PMID 32102933 ↗ Feb 2020 “Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11” NCT00258245 ↗ |
| Action | Inhibit | “Ascorbic acid has the ability to inhibit peroxidase and may thus inhibit melanin synthesis.” NCT00172302 ↗ |
| Modality | Other / unclassified | “antioxidant supplementation with vitamins C and E” PMID 20375405 ↗ Apr 2010 |
| Route | Oral | “Oral Vitamin C” NCT00001070 ↗ |